A quarter of adults in the U.S. have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for cardiologists that take such comorbid conditions and their treatment into consideration.

Preventice, developer of the PatientCare Platform and the BodyGuardian Remote Monitoring Sensor and an innovator in software solutions for remote patient care, and eCardio Diagnostics LLC, a leading provider of remote cardiac monitoring products and services, announced today a strategic combination of Preventice and eCardio to drive innovation and growth in remote monitoring systems and mobile health applications. The two companies will now operate as wholly-owned subsidiaries of a newly formed holding company, Preventice, Inc.

Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.

When clinicians are looking for stable ischemic heart disease and obstructive coronary heart disease, are they overusing invasive methods? A group of researchers wondered how frequently angiographies are diagnosing obstructive coronary heart disease. The answer: is it varies.  

The Transcatheter Cardiovascular Therapeutics (TCT) scientific session begins this weekend in Washington, D.C., so charge up your mobile devices now.

Acute coronary syndrome patients did not experience benefit from using darapladib in a study published Aug. 31 in JAMA.

In treating with warfarin, do physicians know best? New Zealand doctors second guessing an algorithm for anticoagulant dosing did not achieve superior results, according to a study published Sept. 2 in BMJ Open.

The FDA’s Cardiovascular and Renal Drug Advisory Committee will meet Sept. 9 and 10 to review a proposed treatment for hypertension and discuss other fixed-dose combinations.